US 12,134,654 B2
Multispecific molecules and uses thereof
Andreas Loew, Boston, MA (US); Brian Edward Vash, Cambridge, MA (US); and Stephanie J. Maiocco, Arlington, MA (US)
Assigned to MARENGO THERAPEUTICS, INC., Cambridge, MA (US)
Appl. No. 16/605,936
Filed by MARENGO THERAPEUTICS, INC., Cambridge, MA (US)
PCT Filed Apr. 19, 2018, PCT No. PCT/US2018/028315
§ 371(c)(1), (2) Date Oct. 17, 2019,
PCT Pub. No. WO2018/195283, PCT Pub. Date Oct. 25, 2018.
Claims priority of provisional application 62/487,061, filed on Apr. 19, 2017.
Prior Publication US 2020/0071417 A1, Mar. 5, 2020
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 5/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/3061 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/2866 (2013.01); C07K 16/2893 (2013.01); C07K 16/2896 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01)] 12 Claims
 
1. A multispecific antibody molecule comprising:
(i) a single anti-CSF1R binding moiety, wherein the anti-CSF1R binding moiety comprises three complementarity-determining regions (CDRs) from a heavy chain variable region sequence of: SEQ ID NO: 48, SEQ ID NO: 66, or SEQ ID NO: 69; and three CDRs from a light chain variable region sequence of: SEQ ID NO: 50, SEQ ID NO: 67, or SEQ ID NO: 70; and
(ii) an anti-CCR2 binding moiety, wherein the anti-CCR2 binding moiety comprise comprises three CDRs from a heavy chain variable region sequence of: SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 59, SEQ ID NO: 62, or SEQ ID NO: 64; and three CDRs from a light chain variable region sequence of: SEQ ID NO: 45, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 63, or SEQ ID NO: 65;
wherein the multispecific antibody molecule:
binds to CSF1R monovalently,
does not reduce CSF1-dependent bone marrow-derived monocyte differentiation in vitro by more than 10%, and
does not reduce the number of tissue-resident macrophages in vivo by more than 15% when administered to a mammalian subject.